Keyword Analysis & Research: pfizer biontech
Keyword Research: People who searched pfizer biontech also searched
Search Results related to pfizer biontech on Search Engine
-
Pfizer–BioNTech COVID-19 vaccine - Wikipedia
https://en.wikipedia.org/wiki/Pfizer%E2%80%93BioNTech_COVID-19_vaccine
WebThe Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials, logistics, and manufacturing.
DA: 29 PA: 75 MOZ Rank: 3
-
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full …
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-covid-19-vaccine-comirnatyr-receives-full
WebDec 11, 2020 · COMIRNATY is the first COVID-19 vaccine to be granted approval by the FDA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210823005499/en/ The vaccine has been available in the U.S. under Emergency Use Authorization (EUA) since December 11, 2020 …
DA: 79 PA: 99 MOZ Rank: 47
-
Pfizer-BioNTech COVID-19 Vaccine | Pfizer
https://www.pfizer.com/products/product-detail/pfizer-biontech-covid-19-vaccine
WebPfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) has not been approved or licensed by FDA, but has been authorized for emergency use by FDA, under an EUA to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 6 months through 11 years of age.
DA: 48 PA: 49 MOZ Rank: 10
-
Pfizer and BioNTech Announce Further Details on Collaboration …
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-further-details-collaboration
WebApr 9, 2020 · Under the terms of the agreement, Pfizer will pay BioNTech $185 million in upfront payments, including a cash payment of $72 million and an equity investment of $113 million. BioNTech is eligible to receive future milestone payments of up to $563 million for a potential total consideration of $748 million.
DA: 47 PA: 70 MOZ Rank: 72
-
Pfizer and BioNTech Celebrate Historic First Authorization in the …
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-celebrate-historic-first-authorization
WebThe vaccine is now authorized under an Emergency Use Authorization (EUA) while Pfizer and BioNTech gather additional data and prepare to file a planned Biologics License Application (BLA) with the FDA for a possible full regulatory approval in …
DA: 95 PA: 45 MOZ Rank: 36
-
Pfizer-BioNTech COVID-19 Vaccine | FDA
https://www.fda.gov/vaccines-blood-biologics/coronavirus-covid-19-cber-regulated-biologics/pfizer-biontech-covid-19-vaccine
WebSep 11, 2023 · The Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) is authorized for all doses administered to individuals 6 months through 11 years of age to prevent COVID-19. The Pfizer-BioNTech...
DA: 32 PA: 83 MOZ Rank: 7
-
FDA Approves First COVID-19 Vaccine | FDA
https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine
WebAug 23, 2021 · For Immediate Release: August 23, 2021. Español. Today, the U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19...
DA: 40 PA: 99 MOZ Rank: 64
-
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data …
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-updated-covid-19-vaccine-data
WebAug 23, 2022 · NEW YORK & MAINZ, Germany-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced updated efficacy results from a Phase 2/3 trial evaluating a three 3-µg dose series of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months through 4 years of age, reinforcing previously reported interim vaccine …
DA: 62 PA: 10 MOZ Rank: 62
-
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High …
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-phase-3-trial-data-showing
WebSep 22, 2021 · NEW YORK & MAINZ, Germany-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced topline results from a Phase 3 randomized, controlled trial evaluating the efficacy and safety of a 30-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine in more than 10,000 individuals 16 years of age and …
DA: 29 PA: 67 MOZ Rank: 55
-
Pfizer and BioNTech Announce Vaccine Candidate Against COVID …
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against
WebNov 9, 2020 · NEW YORK & MAINZ, GERMANY-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim …
DA: 63 PA: 13 MOZ Rank: 51